Selegiline may be toxic in presence of increased dopamine concentrations

BMJ

Volumn 312, Issue 7032, 1996, Pages 703-704

  Yu, P H ^a   Lai, C T ^a   Boulton, A A ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; DOPAMINE; LEVODOPA; SELEGILINE;

DOSE RESPONSE; DRUG COMBINATION; HUMAN; METABOLISM; MORTALITY; NOTE; PARKINSON DISEASE;

ANTIPARKINSON AGENTS; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HUMANS; LEVODOPA; PARKINSON DISEASE; SELEGILINE;

EID: 85047694873     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.312.7032.703b     Document Type: Letter

References (3)

1. Lees AJ on behalf of the Parkinson's Disease Research Group of the United Kingdom. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. BMJ 1995; 311: 1602–7. (16 December.)
2. Yu PH, Davis BA, Zuo DM, Zhang X, Fang J, Lai CT, et al. Neurochemical, neuroprotective and neurorescue effects of 2-hexyl N-methylpropargylamine (2-HxMP), a new MAO-B inhibitor without amphetamine-like properties. Prog Brain Res 1995; 106: 113–121.
3. Yu PH, Davis BA, Boulton AA. Aliphatic propargylamines: potent selective irreversible monoamine oxidase B inhibitors. J Med Chem 1992; 35: 3705–13.